Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) $40.5 billion purchase of Allergan Plc’s generics unit, which closed on Aug. 2, doesn’t signal that the Israeli drugmaker will let up its quest for innovative branded medicines.

Efforts to introduce new copycat drugs and integrate operations gained through its largest acquisition “doesn’t mean we confine our business to just generics,” chief executive officer Erez Vigodman said in an interview at Teva’s headquarters in Petach Tikva, Israel. “The strategy and vision are much broader.”

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.